2001
DOI: 10.1016/s0149-2918(01)80142-9
|View full text |Cite
|
Sign up to set email alerts
|

Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2004
2004
2007
2007

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 76 publications
0
2
0
Order By: Relevance
“…Perfetto et al (20) recommended that patient-reported outcomes of work loss and productivity level at work be included as endpoints in studies of AECB. However, most of the studies reviewed in this manuscript, as well as most studies evaluating diseaserelated workplace absenteeism in general, rely on selfreported data for days of work missed.…”
Section: Discussionmentioning
confidence: 99%
“…Perfetto et al (20) recommended that patient-reported outcomes of work loss and productivity level at work be included as endpoints in studies of AECB. However, most of the studies reviewed in this manuscript, as well as most studies evaluating diseaserelated workplace absenteeism in general, rely on selfreported data for days of work missed.…”
Section: Discussionmentioning
confidence: 99%
“…There have been few studies addressing this issue, the results of which are applicable on a large-scale. (24) In a retrospective study, the use of third-generation antibiotics (azithromycin, ciprofloxacin and amoxicillin/clavulanic acid) in comparison to that of first-generation antibiotics (amoxicillin, sulfamethoxazole/trimethoprim, erythromycin and tetracycline) was found to be associated with lower rates of treatment failure/ hospitalization, longer intervals between exacerbation episodes and (a tendency toward) lower overall treatment costs. (25) The results of the present study confirm the efficacy and tolerability of azithromycin for the outpatient treatment of episodes of infectious exacerbation of COPD.…”
Section: Discussionmentioning
confidence: 99%